Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications

In medicine: Prophylaxis and therapy of hemophtoes, digestive hemorrhages, hemorrhagic syndromes in leukaemia, cirrhosis and hemophilia, thrombocytopenic purpura, accidents during thrombolytic therapy and transfusion.In surgery: Prophylaxis and antihemorrhagic ... Read moreIn medicine: Prophylaxis and therapy of hemophtoes, digestive hemorrhages, hemorrhagic syndromes in leukaemia, cirrhosis and hemophilia, thrombocytopenic purpura, accidents during thrombolytic therapy and transfusion.In surgery: Prophylaxis and antihemorrhagic therapy during operations of any type and nature and particularly in pulmonary, cardiovascular and abdominal surgery and post-operative and traumatic shock.In urology: Prophylaxis and antihemorrhagic therapy of prostatic, vesical and renal surgery. Hematurias.In obstetrics: Prophylaxis and therapy of post-partum and puerperium hemorrhages, hemorrhagic metrophathies, functional menometrorrhagias, idiopathic or IUD (lntra uterine Device) induced menorrhagias, primitive hyperfibrinolysis (abruptio placentae, premature placenta detachment) and in cervical conization.In otorhinolaryngology: Prophylaxis and antihemorrhagic therapy during a tonsillectomy, specialist surgery generally, epistaxis.In stomatology: Prophylaxis and antihemorrhagic therapy during maxillofacial operations, tooth extractions.In oncology (as supportive therapy): To promote the formation of a fibrin capsule to wall off and thereby inhibit the growth of ovarian tumors. To cause regression of ascites secondary to carcinoma. To reduce bleeding during surgical interventions.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

This is a preparation of tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid). Tranexamic acid is a substance endowed with a strong antifibrinolytic action and both in vivo and in vitro it has proved to be 10 times more active than conventional hemostatics, depending on the test. The antihemorrhagic action of tranexamic acid is essentially due to an inhibition of the plasminogen activation of both exogenous activators like streptokinase and endogenous ones like urokinase and the plasminogen tissue activator. This fact is particularly important for the clinical use of Tranexamic Acid, because it ensures an antihemorrhagic activity with an antifibrinolytic mechanism under a variety of conditions.The acute toxicity of Tranexamic Acid is extremely low and chronic toxicity almost non-existent. Tranexamic Acid is well absorbed by oral route and the effect is already seen 15-30 minutes after administration. It is excreted mainly by renal route but more slowly than conventional hemostatics. These features make the Tranexamic Acid effect more lasting than those conventional hemostatics. Considerably lower single doses of Tranexamic Acid can thus be administered at greater intervals without the drug plasma levels dropping to inefficient levels of antifibrinolytic activity between one dose and the other.Tranexamic Acid at therapeutic doses does not interfere with clotting processes and even a prolonged administration has not been seen to be accompanied by any tendency to thrombophilia.

Pregnancy & Breastfeeding

Since it is not known whether the drug crosses the placenta or what effect it might have on a developing baby, Tranexamic Acid should not be given during known or suspected pregnancy. Tranexamic Acid does pass into breast milk, but only at roughly one hundredth of the concentration found in the mother's blood, so it is unlikely to have any antifibrinolytic effect on the infant.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Adults: The usual dose is 500 to 1000 mg, three times daily. For prophylaxis, the mean recommended daily dose is 0.5 to 1 gm by mouth, or 500 mg by the parenteral (intravenous or intramuscular) route. For treatment of hemorrhagic manifestations, the oral dose is increased to 1 to 3 gm given in divided doses. In cases of particular seriousness and urgency, treatment may begin with an ampoule (500 mg) injected slowly by the intravenous route, followed by the necessary oral doses. Children: For prophylaxis, 5 to 10 mg for every kg of body weight is given orally each day in divided doses. For therapeutic purposes, the oral dose is doubled, from 10 to 20 mg/kg, while intravenous or intramuscular treatment is begun with 10 mg/kg (equal to 0.5 ml for every 5 kg) given slowly by the intravenous route, continuing with oral doses up to the amount required. Where more convenient, such as in small babies, the ampoules may be diluted in a little sweetened water and given orally instead of the capsules. Elderly patients: No reduction in dosage is necessary unless there is evidence of renal failure.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.